Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016923
Chunk: 162

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 162
---
umSmith+Brown, PC, independent registered public accounting firm, as set forth in their report thereon (which contains an explanatory paragraph describing conditions that raise substantial doubt about bioAffinity Technologies, Inc.’s ability to continue as a going concern as described in Note 1 to the consolidated financial statements) appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing.

<div align='center'>LEGAL MATTERS</div>

The validity of the securities offered hereby will be passed upon for us by Blank Rome LLP, New York, New York.

<div align='center'>WHERE YOU CAN FIND ADDITIONAL INFORMATION</div>

We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy statements and other information filed electronically with the SEC, which is available at http://www.sec.gov. We also make these documents available on our website at https://www.bioaffinitytech.com/. Our website and the information contained, or connected to, our website is not incorporated by reference in this prospectus and you should not consider it part of this prospectus.

This prospectus forms part of the registration statement on Form S-1 we filed with the SEC under the Securities Act. This prospectus does not contain all of the information set forth in the registration statement or the exhibits and schedules filed as part of the registration statement. For further information about us and our securities offered hereby, we refer you to the registration statement and the exhibits and schedules filed therewith. Statements contained in this prospectus regarding the contents of any contract or other document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the registration statement.

| 95 |

GLOSSARY OF SELECTED TERMS

| Adenocarcinoma    |     | A                                                                                                                                          
 form of cancer that forms in the tissue that lines certain internal organs. Most cancers of the breast, pancreas, lung, prostate,          
 colon, esophagus, and stomach are adenocarcinomas.                                                                                         |
| Antibody          |     | A                                                                                                                                          
 protein that is produced by a person’s immune system to target and destroy alien substances in the blood such as bacteria or               
 viruses.                                                                                                                                   |
| Bio-label         |     | A                                                                                                                                          
 tag that is chemically attached to an individual cell. These tags,